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BY FRANK A. WOLLHEIM
Department of Rheumatology, Lund University Hospital, S-221 85 Lund, SwedenTHE exact role of the subchondral bony plate in
osteoarthritis in man is unclear, since studies to
date have been confined to spontaneous and
induced experimental models in animals.
Histologic material from man is rarely available
and the microscopic anatomy cannot be studied in
prospective studies. In order to explore the role of
the subchondral bone as target for therapy, one
might consider molecular markers of bone activity
as an indirect measure of bone metabolism.Bone sialoprotein
Bone sialoprotein (BSP) was isolated in Dick
Heinega˚rd’s laboratory in 1985 [1, 2]. BSP is a
57 kDa non-collagenous matrix protein with
strong binding a$nity for cells and for hydroxya-
patite. It contains an RDG group and its mRNA is
upregulated by dexamethasone. BSP is highly con-
served in mammals [3]. In experimental osteo-
arthritis in the guinea pig, BSP was initially con-
centrated at the osteocartilaginous interface [4].
In later stages, BSP was more abundant in parts of
the bone a#ected by the osteoarthritis [4].
In patients with rheumatoid arthritis, increased
knee joint synovial fluid BSP levels correlated
with destruction in that joint. Serum levels of BSP
were also increased [5].
BSP was compared to osteocalcin (GLA). GLA is
also increased in rheumatoid arthritis, but does
not correlate with joint destruction. GLA has the
disadvantage of being less stabile in vitro.
BSP has also been studied in knee joint injury
where increased levels were found for at least a
month following the injury [6].
Serum BSP levels correlated with progression
of osteoarthritis in a prospective population
based cohort, along with the cartilage marker,
COMP [7]. Both markers also correlated to
increased articular localization of the nuclide on
scintigraphic examination [8].
In conclusion, BSP appears to be a potentially
useful marker for juxta-articular bone in osteo-
arthritis.331Therapeutic implications
A potential pharmacological approach may
target reducing subchondral bone metabolism,
particularly in early disease
Some bisphosphonates have been used to
prevent heterotopic ossification in connection
with hip replacement surgery [9]. Yet, I have
found no recent published reports on the use of
bisphosphonates in osteoarthritis.
Growth factors have been postulated to play a
role in the hypertrophy of subchondral bone [10].
Insulin like growth factor (IGF), may be of key
importance in understanding the pathogenesis
of osteoarthritis, and may form the basis for
designing new therapeutic approaches [11, 12].
Ideally drug therapy in osteoarthritis should be
directed to early pathogenic events in the disease
process. Since there is evidence that subchondral
bone is involved early in osteoarthritis, attempts
to interfere with bone metabolism appears of
special interest.References
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